Is universal coronavirus immunity possible?

T-cell immunity is essential for positive clinical outcomes of SARS-CoV-2 infection. Hence, T-cell-focused cellular immunotherapy or vaccination might prove instrumental in enhancing coronavirus disease 2019 (COVID-19) protection among immunocompromised (IP) patients. Pre-existing T-cell memory identifying SARS-CoV-2 antigens preceding COVID-19 vaccination or infection may be developed because of prior infections with endemic non-SARS human CoVs (hCoVs). Thus, SARS-CoV-2-primed T cells may detect emerging SARS-CoV-2 variants or other hCoV viruses and alter the course of following hCoV infections. However, cross-immunity between SARS-CoV-2 and hCoVs needs extensive investigation.

Study: The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses. Image Credit: kittipong053 / Shutterstock

About the study

In the present study, researchers explored the T-cell responses observed against the immunodominant SARS-CoV-2 and hCoV membrane (M), nucleocapsid (N), and spike (S) proteins.

The team assessed serial peripheral blood mononuclear cell (PBMC) samples obtained from healthy volunteers and immunocompromised individuals who did or did not report SARS-CoV-2 exposure to estimate T-cell responses against hCoVs like NL63, OC43, HKU1, and 229E, and SARS-CoV-2. Reactivity to associated immunodominant antigens was tested from among related common Alpha- and beta-hCoVs in the same sample donor.

Furthermore, the researchers determined whether previously acquired vaccination-induced or natural T-cell immunity cross-reacted against SARS-CoV-2 variants. This was achieved by obtaining PBMCs from COVID-19-positive and unexposed individuals vaccinated with at least one SARS-CoV-2 vaccine. The resultant T-cells were further assessed for reactivity against eight SARS-CoV-2 variants of concern (VOCs). The team characterized the range of T-cell responses against hCoV by testing ex vivo reactivity using pepmixes derived from N, M, S1, and S2 antigens associated with endemic hCoVs. Additionally, the extent of responses against hCoVs in COVID-19-positive and -negative donors was assessed.

Results

The study results showed that one of the subjects, a healthcare worker, developed COVID-19 almost three months after collecting the initial sample. T-cell responses recorded at baseline against SARS-CoV-2 N, M, S1, and S2 antigens were slightly detectable against the background, confirming the naive/unexposed status. Post-COVID-19 samples revealed a remarkable rise in reactivity against the four SARS-CoV-2 antigens prevalent in the CD4+ T cell compartment. The team noted maximal reactivity against the N protein antigen, followed by M, S2, and S1. The pattern and magnitude of reactivity against the non-SARS hCoV targets before and after COVID-19 stayed low and were negligibly impacted by COVID-19. Therefore, this particular sample donor had highly focused and robust antigen-specific T-cell memory against SARS-CoV-2 after infection.

The team noted that COVID-19-exposed donors largely maintained the overall SARS-CoV-2-specific CD4+ T-cell response against the eight assessed VOCs. Mean reductions of almost 27.8% against SARS-CoV-2 Beta, 16.2% against Gamma, and 22.5% against Epsilon VOCs were observed. Additionally, a reduction of 8.5% was noted against Alpha, 5.2% against Delta, and 0.83% against Kappa VOCs. However, the highest reduction of almost 47% was noted against the Omicron VOC.

On an individual level, the highest reduction of 33-fold was reported in one COVID-19-positive IP patient against the Omicron variant, and two other donors revealed a two-fold reduction. Notably, none of the donors displayed a reduction of over 10-fold in the extent of CD4+ T cell response against other variants. While three donors reported a two-fold reduction in reactivity against the Beta variant, some reported an over two-fold reduction against the Delta, Kappa, and Eta variants compared to the ancestral pool. Altogether, all tested COVID-19 survivors that displayed reactivity against the WT-peptide pool also exhibited the cross-recognition of other variants against Delta.

The team noted that both COVID-19-positive and -negative donors displayed robust but highly inconsistent antigen-specific CD8+ responses. Overall, reactivity to a minimum of one antigen associated with each hCoV was observed among all the tested subjects. However, the simultaneous robust response against the four antigens related to each hCoV was remarkably more predominant among COVID-19-positive samples than in the -negative ones.

Furthermore, considerably higher reactivity was observed against the S1 antigen of hCoVs NL63 and OC43 among COVID-19 survivors in comparison to SARS-CoV-2-negative individuals. Higher reactivity was also noted against S2 antigens of NL63 and HKU1, which rose further against S2 antigens of 229E and OC43. The team also found a significant association between COVID-19 responses and corresponding responses targeted against S2 and M of OC43 as well as N antigens of HKU1 and OC43. Overall, this indicated a potential association between T-cell immunity elicited after SARS-CoV-2 infection and reactivity directed against other hCoVs. This further suggested possible cross-reactivity and potential cross-protection.

Conclusion

The study findings highlighted broad T-cell immunity against the SARS-CoV-2 antigens observed in COVID-19 survivors. In vaccinated and in convalescent individuals, SARS-CoV-2 S-specific T-cells effectively detected the majority of the SARS-CoV-2 variants. However, cross-reactivity against the SARS-CoV-2 Omicron variant was decreased by almost 50%. Responses against the N, S, and M antigens from the endemic hCoVs were found in higher proportions among COVID-19 survivors than among unexposed individuals. The researchers believe that the present study supported the hypothesis that vaccines with broadly-specific anti-CoV T-cells could provide effective immunotherapies.

*Important notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:

The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses, Mithil K Soni, Edoardo Migliori, Jianing Fu, Amer Assal, Hei Ton Chan, Jian Pan, Prabesh Khatiwada, Rodica Ciubotariu, Michael S May, Marcus R Pereira, Valeria De Giorgi, Megan Sykes, Marcus Y Mapara, Pawel Muranski, bioRxiv 2023.01.03.519511, DOI: https://doi.org/10.1101/2023.01.03.519511, https://www.biorxiv.org/content/10.1101/2023.01.03.519511v1

lisa1 lisa2 lisa3 lisa4 lisa5 lisa6 lisa7 lisa8 lisa9 lisa10 lisa11 lisa12 lisa13 lisa14 lisa15 lisa16 lisa17 lisa18 lisa19 lisa20 lisa21 lisa22 lisa23 lisa24 lisa25 lisa26 lisa27 lisa28 lisa29 lisa30 lisa31 lisa32 lisa33 lisa34 lisa35 lisa36 lisa37 lisa38 lisa39 lisa40 lisa41 lisa42 lisa43 lisa44 lisa45 lisa46 lisa47 lisa48 lisa49 lisa50 lisa51 lisa52 lisa53 lisa54 lisa55 lisa56 lisa57 lisa58 lisa59 lisa60 lisa61 lisa62 lisa63 lisa64 lisa65 lisa66 lisa67 lisa68 lisa69 lisa70 lisa71 lisa72 lisa73 lisa74 lisa75 lisa76 lisa77 lisa78 lisa79 lisa80 lisa81 lisa82 lisa83 lisa84 lisa85 lisa86 lisa87 lisa88 lisa89 lisa90 lisa91 lisa92 lisa93 lisa94 lisa95 lisa96 lisa97 lisa98 lisa99 lisa100 lisa101 lisa102 lisa103 lisa104 lisa105 lisa106 lisa107 lisa108 lisa109 lisa110 lisa111 lisa112 lisa113 lisa114 lisa115 lisa116 lisa117 lisa118 lisa119 lisa120 lisa121 lisa122 lisa123 lisa124 lisa125 lisa126 lisa127 lisa128 lisa129 lisa130 lisa131 lisa132 lisa133 lisa134 lisa135 lisa136 lisa137 lisa138 lisa139 lisa140 lisa141 lisa142 lisa143 lisa144 lisa145 lisa146 lisa147 lisa148 lisa149 lisa150 lisa151 lisa152 lisa153 lisa154 lisa155 lisa156 lisa157 lisa158 lisa159 lisa160 lisa161 lisa162 lisa163 lisa164 lisa165 lisa166 lisa167 lisa168 lisa169 lisa170 lisa171 lisa172 lisa173 lisa174 lisa175 lisa176 lisa177 lisa178 lisa179 lisa180 lisa181 lisa182 lisa183 lisa184 lisa185 lisa186 lisa187 lisa188 lisa189 lisa190 lisa191 lisa192 lisa193 lisa194 lisa195 lisa196 lisa197 lisa198 lisa199 lisa200 lisa201 lisa202 lisa203 lisa204 lisa205 lisa206 lisa207 lisa208 lisa209 lisa210

NewToNews

Is universal coronavirus immunity possible?

Byolaksjl

About the study

Results

Conclusion

*Important notice

By olaksjl

Related Post

What if Only 11% of Cancer Patients or Diabetics Were Treated for Their Disease?

COVID-19 During Pregnancy Increases Risk Of Brain Disorders In Male Babies

US TB Incidence Rate Returning To Pre-Pandemic Levels: CDC

Leave a Reply Cancel reply

You missed

All SAEs including death should be reported: CDSCO Panel tells AstraZeneca about Durvalumab

Meta Pixel offers benefits, risks for practice website management

CDSCO panel tells Laurus Labs on Carglumic Acid Dispersible Tablets

US federal court ruling could result in 2,000 new HIV infections among MSM each year

NewToNews